Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

June 8 (UPI) --The U.S. Food and Drug Administration approved GSK's respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the shot's accessibility to younger patients.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

GSK GSK-0.42%decrease; red down pointing triangle shares plunged after U.S. health officials narrowed their recommendation of respiratory syncytial virus vaccines to a smaller age range and more ...

The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50. GSK, the vaccine’s maker, announced ...

The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased risk. The FDA has granted an expanded age indication for GSK’s Arexvy for the ...

"Current vaccine recommendations continue to stratify by age but need to better incorporate risk from the presence of chronic medical conditions at any age." — Angela Branche, MD, Associate Professor ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to ...